BONG-WOO PARK

Prof. BONG-WOO PARK

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
SPSoon-Jung Park
Soon-Jung Park
RKRi Youn Kim
Ri Youn Kim
BPBONG-WOO PARK
BONG-WOO PARK
SLSunghun Lee
Sunghun Lee
SCSeong Woo Choi
Seong Woo Choi
HPHun-Jun Park
Hun-Jun Park
Since both myocardium and vasculature in the heart are excessively damaged following myocardial infarction (MI), therapeutic strategies for treating MI hearts should concurrently target both so as to achieve true cardiac repair. Here we demonstrate a concomitant method that exploits the advantages of cardiomyocytes derived from human induced pluripotent stem cells (hiPSC-CMs) and human mesenchymal stem cell-loaded patch (hMSC-PA) to amplify cardiac repair in a rat MI model. Epicardially implanted hMSC-PA provide a complimentary microenvironment which enhances vascular regeneration through prolonged secretion of paracrine factors, but more importantly it significantly improves the retention and engraftment of intramyocardially injected hiPSC-CMs which ultimately restore the cardiac function. Notably, the majority of injected hiPSC-CMs display adult CMs like morphology suggesting that the secretomic milieu of hMSC-PA constitutes pleiotropic effects in vivo. We provide compelling evidence that this dual approach can be a promising means to enhance cardiac repair on MI hearts.

1 May 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
JLJu-Ro Lee
Ju-Ro Lee
BPBONG-WOO PARK
BONG-WOO PARK
JKJonghoon Kim
Jonghoon Kim
YCYeon Woong Choo
Yeon Woong Choo
Han Young KimHan Young Kim
Han Young Kim
BKByung-Soo Kim
Byung-Soo Kim
Increased therapeutic factors and retention of IONP-NVs substantially enhance therapeutic potential for cardiac repair.

22 October 2019 in Applied Physics Reviews
Verified
Journal Article
Closed access
PDF file
Ge GaoGe Gao
Ge Gao
HKHyeok Kim
Hyeok Kim
BKByoung Soo Kim
Byoung Soo Kim
JKJeong Sik Kong
Jeong Sik Kong
JLJae Yeon Lee
Jae Yeon Lee
Dong-Woo ChoDong-Woo Cho
Dong-Woo Cho
Tissue engineering has emerged as a promising approach to viable small-diameter vascular grafts that may be used to treat cardiovascular diseases. One challenge in constructing such blood vessels is proper localization of endothelial cells and smooth muscle cells, as well as promotion of their cellular functions to generate functional tissues. Thus far, construction of small-diameter vascular substitutes with both endothelial and muscular tissues, which is essential for the grafts to acquire antithrombosis function and sufficient strength to avoid thrombus formation as well as to withstand blood pressure, has not yet been demonstrated. In this study, we engineer small-diameter blood vessel grafts containing both functional endothelial and muscular cell layers, which has been demonstrated in vivo in a living rat model. Our construction of the blood vessel grafts uses vascular-tissue-derived extracellular matrix bioinks and a reservoir-assisted triple-coaxial cell printing technique. The prematured vessel was implanted for three weeks as a graft of rat abdominal aorta in a proof-of-concept study where all implants showed great patency, intact endothelium, remodeled smooth muscle, and integration with host tissues at the end of the study. These outcomes suggest that our approach to tissue-engineered biomimetic blood vessels provides a promising route for the construction of durable small-diameter vascular grafts that may be used in future treatments of cardiovascular diseases.

27 March 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
BPBONG-WOO PARK
BONG-WOO PARK
SJSoo-Hyun Jung
Soo-Hyun Jung
SDSanskrita Das
Sanskrita Das
SLSoon Min Lee
Soon Min Lee
JPJae-Hyun Park
Jae-Hyun Park
HPHun-Jun Park
Hun-Jun Park
Priming human BM-MSCs with engineered HGF-MSCs in vivo significantly improves therapeutic potential for myocardial infarction.

15 October 2021 in Antioxidants
Verified
Journal Article
Open access
PDF file
HJHwang Ji-Won
Hwang Ji-Won
JPJae-Hyun Park
Jae-Hyun Park
BPBONG-WOO PARK
BONG-WOO PARK
HKHyeok Kim
Hyeok Kim
JKJin-Ju Kim
Jin-Ju Kim
SBSang Hong Baek
Sang Hong Baek
Reactive oxygen species (ROS) and intracellular iron levels are critical modulators of lipid peroxidation that trigger iron-dependent non-apoptotic ferroptosis in myocardial ischemia-reperfusion (I/R) injury. Histochrome (HC), with a potent antioxidant moiety and iron-chelating capacity, is now available in clinical practice. However, limited data are available about the protective effects of HC on ferroptotic cell death in myocardial I/R injury. In this study, we investigated whether the intravenous administration of HC (1 mg/kg) prior to reperfusion could decrease myocardial damage by reducing ferroptosis. Rats undergoing 60 min of ischemia and reperfusion were randomly divided into three groups as follows: (1) Sham, (2) I/R control, and (3) I/R + HC. Serial echocardiography up to four weeks after I/R injury showed that intravenous injection of HC significantly improved cardiac function compared to the I/R controls. In addition, the hearts of rats who received intravenous injection of HC exhibited significantly lower cardiac fibrosis and higher capillary density. HC treatment decreased intracellular and mitochondrial ROS levels by upregulating the expression of nuclear factor erythroid 2-related factor (Nrf2) and its downstream genes. HC also inhibited erastin- and RSL3-induced ferroptosis in rat neonatal cardiomyocytes by maintaining the intracellular glutathione level and through upregulated activity of glutathione peroxidase 4. These findings suggest that early intervention with HC before reperfusion rescued myocardium from I/R injury by preventing ferroptotic cell death. Therefore, HC is a promising therapeutic option to provide secondary cardioprotection in patients who undergo coronary reperfusion therapy.

16 December 2022 in Science Advances
Verified
Journal Article
Open access
YJYoonhee Jin
Yoonhee Jin
HKHyeok Kim
Hyeok Kim
SMSungjin Min
Sungjin Min
YCYi Sun Choi
Yi Sun Choi
SSSeung Ju Seo
Seung Ju Seo
SCSeung-Woo Cho
Seung-Woo Cho
Direct cardiac reprogramming has emerged as a promising therapeutic approach for cardiac regeneration. Full chemical reprogramming with small molecules to generate cardiomyocytes may be more amenable than genetic reprogramming for clinical applications as it avoids safety concerns associated with genetic manipulations. However, challenges remain regarding low conversion efficiency and incomplete cardiomyocyte maturation. Furthermore, the therapeutic potential of chemically induced cardiomyocytes (CiCMs) has not been investigated. Here, we report that a three-dimensional microenvironment reconstituted with decellularized heart extracellular matrix can enhance chemical reprogramming and cardiac maturation of fibroblasts to cardiomyocytes. The resultant CiCMs exhibit elevated cardiac marker expression, sarcomeric organization, and improved electrophysiological features and drug responses. We investigated the therapeutic potential of CiCMs reprogrammed in three-dimensional heart extracellular matrix in a rat model of myocardial infarction. Our platform can facilitate the use of CiCMs for regenerative medicine, disease modeling, and drug screening.